- Home
- MAIN vs LEGN Comparison
MAIN vs LEGN Comparison
Compare MAIN & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MAIN | LEGN |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.9B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MAIN | LEGN |
|---|---|---|
| Price | $55.13 | $17.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $61.57 | ★ $63.08 |
| AVG Volume (30 Days) | 847.1K | ★ 1.5M |
| Earning Date | 05-07-2026 | 03-10-2026 |
| Dividend Yield | ★ 7.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.95 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.27 | $46.27 |
| Revenue Next Year | $5.14 | $28.77 |
| P/E Ratio | $13.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $47.00 | $16.24 |
| 52 Week High | $67.77 | $45.30 |
Technical Indicators
Market Signals| Indicator | MAIN | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 39.61 | 38.56 |
| Support Level | $55.06 | $16.24 |
| Resistance Level | $59.24 | $20.39 |
| Average True Range (ATR) | 1.35 | 0.80 |
| MACD | -0.00 | -0.14 |
| Stochastic Oscillator | 21.58 | 5.42 |
Price Performance
Historical ComparisonAbout MAIN Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancing, and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants, and other securities of the lower middle market and middle market companies based in the United States. Business functioned through the U.S. region and it derives the majority of its income from the source of fees, commission, and interest.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.